Serotonin induces and maintains visceral hyperactivity by modulating the activation of the transient receptor potential vanilloid 1 (TRPV1) [70]; thus, serotonin receptor agonists or antagonists have been investigated for the treatment of IBS patients [71, 72]. Here, TRPV1 is linked to irritable bowel syndrome.